Antibody Response Dynamics to CoronaVac Vaccine and Booster Immunization in Adults and the Elderly: A Long-term, Longitudinal Prospective Study

Background: The long-term humoral immune response after vaccination varies between vaccines and is dependent on the accuracy of the antibody test. A better understanding of the vaccine immune response may help to define vaccination strategies against coronavirus disease 2019 (COVID-19).

Objective: To investigate the long-term immunological response to CoronaVac vaccine and determinants of breakthrough COVID-19 infection.

Methods: A long-term, prospective cohort study involving vaccinated adult and elderly subjects was conducted to investigate the presence of anti-RBD-specific immunoglobulin (Ig)G, anti-nucleocapsid IgG and anti-spike trimeric protein IgG. Antibody level dynamics and risk factors associated with breakthrough COVID-19 infection were investigated.

Results: In total, 3902 participants were included in this study. Vaccination with two doses of CoronaVac and a booster dose increased the levels of anti-RBD-specific IgG, anti-nucleocapsid IgG and anti-spike trimeric IgG significantly. In adults, anti-nucleocapsid IgG and anti-spike trimeric IgG levels decreased significantly 7 months after the second dose. In adults and the elderly, the levels of anti-spike trimeric IgG and anti-RBD IgG decreased significantly 4 and 6 months after the booster dose, respectively. Previous exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and anti-spike trimeric IgG titres was independently associated with a lower probability of post-vaccination infection.

Conclusions: A significant increase in antibody levels was found after two doses of CoronaVac and a booster dose. Antibody titres declined significantly 7 months post-vaccination in participants who did not receive a booster dose. Higher levels of antibodies and previous SARS-CoV-2 infection were associated with protection against breakthrough COVID-19.

Citing Articles

Post COVID-19 vaccination binding and neutralizing antibody with or without previous infection: An 18-month longitudinal study in Indonesia.

Ardyanto T, Khariri K, Agus T, Soebandrio A Narra J. 2024; 4(2):e1071.

PMID: 39280276 PMC: 11394176. DOI: 10.52225/narra.v4i2.1071.

Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.

do Nascimento T, Nogami P, de Oliveira C, Neto W, da Silva C, Ribeiro A Vaccines (Basel). 2024; 12(7).

PMID: 39066430 PMC: 11281708. DOI: 10.3390/vaccines12070792.

Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly.

Acer O, Bahce Y, Ozudogru O Curr Microbiol. 2024; 81(7):171.

PMID: 38739274 DOI: 10.1007/s00284-024-03689-7.

References

Mekonnen D, Mengist H, Derbie A, Nibret E, Munshea A, He H . Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis. Rev Med Virol. 2020; 31(3):e2181. DOI: 10.1002/rmv.2181. View

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

Leung N, Cheng S, Martin-Sanchez M, Au N, Ng Y, Luk L . Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. Clin Infect Dis. 2022; 76(3):e299-e307. PMC: 9384189. DOI: 10.1093/cid/ciac458. View

Saure D, ORyan M, Torres J, Zuniga M, Santelices E, Basso L . Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2021; 22(1):56-63. PMC: 8428469. DOI: 10.1016/S1473-3099(21)00479-5. View

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

Ferreira N, Garibaldi P, Moraes G, Moura J, Klein T, Machado L . The impact of an enhanced health surveillance system for COVID-19 management in Serrana, Brazil. Public Health Pract (Oxf). 2022; 4:100301. PMC: 9354446. DOI: 10.1016/j.puhip.2022.100301. View

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

Batra M, Tian R, Zhang C, Clarence E, Sacher C, Miranda J . Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021; 11(1):3455. PMC: 7875990. DOI: 10.1038/s41598-021-83108-0. View

10.

Gustafson C, Kim C, Weyand C, Goronzy J . Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020; 145(5):1309-1321. PMC: 7198995. DOI: 10.1016/j.jaci.2020.03.017. View

11.

Palacios R, Patino E, Piorelli R, Conde M, Batista A, Zeng G . Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary.... Trials. 2020; 21(1):853. PMC: 7558252. DOI: 10.1186/s13063-020-04775-4. View

12.

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

13.

Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R . Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. PMC: 8135422. DOI: 10.1093/cid/ciab381. View

14.

Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M . Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021; 600(7890):701-706. DOI: 10.1038/s41586-021-04120-y. View

15.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6):803-812. PMC: 7906628. DOI: 10.1016/S1473-3099(20)30987-7. View

16.

Marra A, Miraglia J, Malheiros D, Guozhang Y, Teich V, da Silva Victor E . Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021. Clin Infect Dis. 2022; 76(3):e360-e366. PMC: 9213833. DOI: 10.1093/cid/ciac430. View

17.

Tober-Lau P, Schwarz T, Vanshylla K, Hillus D, Gruell H, Suttorp N . Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respir Med. 2021; 9(11):e104-e105. PMC: 8528470. DOI: 10.1016/S2213-2600(21)00456-2. View

18.

Tanriover M, Doganay H, Akova M, Guner H, Azap A, Akhan S . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296):213-222. PMC: 8266301. DOI: 10.1016/S0140-6736(21)01429-X. View

19.

B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50. PMC: 9017870. DOI: 10.1126/science.abm3425. View

20.

Fenwick C, Croxatto A, Coste A, Pojer F, Andre C, Pellaton C . Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2020; 95(3). PMC: 7925109. DOI: 10.1128/JVI.01828-20. View